Faheem Hasnain

Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA.

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA.

Oncology Therapeutics Network Corp. distributes pharmaceuticals to oncologists. It also provides support services. The company was founded in 1990 and is headquartered in South San Francisco, CA.

PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV.

Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016.

Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA.

SENTÉ, Inc. provides skin care products. The firm's products include Daily Repair Complex, Neck Firming and Redness Control Complex creams. It offers dermal repair cream for people of various age groups and skin types for enhancing the skin tone, texture, elasticity, and overall appearance. The company serves customers through dermatologists and physicians in the United States. Sente was founded by Kleanthis G. Xanthopoulos and Marios Fotiadis in 2007 and is headquartered in Carlsbad, CA.

Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA.

Vertex Ventures HC (Vertex Ventures) is a venture capital subsidiary of Vertex Venture Holdings Ltd founded in 2014. The firm is headquartered in San Francisco, California.

Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA.

Panacea Acquisition Corp. is a blank check company with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in April 2020 and is headquartered in San Francisco, CA.

Sling Therapeutics, Inc. is a company dedicated to developing impactful and high-quality clinical therapies for patients. Sling Therapeutics is located in Ann Arbor, MI and was founded by Gary D. Hammer. The company's pipeline includes linsitinib, an oral therapy being developed for thyroid eye disease (TED) that has established a safety profile through treatment of over 800 patients. The company is focused on bringing additional treatment options to patients, as well as the ophthalmology, endocrinology, and rare disease communities. Sling Therapeutics welcomes collaboration in this mission. The CEO is Ryan Zeidan.